CN102579678B - Medicinal composition for treating vitligo - Google Patents
Medicinal composition for treating vitligo Download PDFInfo
- Publication number
- CN102579678B CN102579678B CN 201210103185 CN201210103185A CN102579678B CN 102579678 B CN102579678 B CN 102579678B CN 201210103185 CN201210103185 CN 201210103185 CN 201210103185 A CN201210103185 A CN 201210103185A CN 102579678 B CN102579678 B CN 102579678B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- treatment
- pharmaceutical composition
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 28
- 241000756943 Codonopsis Species 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000241463 Cullen corylifolium Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241001106477 Paeoniaceae Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 40
- 239000003814 drug Substances 0.000 description 25
- 206010047642 Vitiligo Diseases 0.000 description 22
- 230000017531 blood circulation Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 10
- 210000002752 melanocyte Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000028280 polygenic inheritance Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal composition for treating vitligo. The medicinal composition comprises the following components in parts by weight: 12-30 parts of rehmannia root, 12-25 parts of Chinese angelica, 12-25 parts of red paeony root, 10-25 parts of suberect spatholobus stem and 6-15 parts of malaytea scurfpea fruit. The invention provides a medical composition for treating vitligo, which has high curing rate, is safe and is free from toxic and side effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, relate to a kind of leukodermic pharmaceutical composition that is used for the treatment of.
Background technology
Vitiligo is a kind of common pigment obstacle dermatoses, is one of the world's dermopathic three big pertinacious diseases.Its Clinical symptoms shows as mainly that melanocyte reduces or disappears and the depigmentation speckle occurs.Its harm has a strong impact on patient's appearance, psychology, work and inter personal contact.Epidemiological study to 4292 routine patients shows that about 64.3% patient just sent out the age less than 20 years old, these children and between twenty and fifty patient's great majority have personal lifestyle and psychological puzzlement in various degree, and have influence on their life, work, a lot of aspects such as marriage, the patient of part psychologically handicapped even for this reason sprout the thought commit suicide has brought huge pressure also for family and society.Therefore, early prevention and effective treatment vitiligo are paid close attention to widely.Because present leukodermic pathogenesis is still undistinct, so its treatment is still relatively more difficult.
Modern medicine thinks that vitiligo is that polygenic inheritance is the basis, the disease of multifactor fellowship, and its cause of disease is main relevant with factors such as oxidative stress, autoimmune, endocrine, heredity.Motherland's medical science has very early to leukodermic record, be called " leucoderma ", " vitiligo ", " vitiligo " etc., the record of " face and neck health skin and flesh complexion changed are white; different with yellowish pink; the pain of also not itching; the leucoderma of meaning " is namely arranged in " General Treatise on the Cause and Symptoms of Diseases " of Sui Dynasty Chao Yuanfang (550-630 A.D.), think that the leukodermic cause of disease belongs to depression of liver-QI more, deficiency of both the liver and kidney, ailment said due to cold or exposure visitor is in the skin space between skin and muscles, qi-blood disharmony, with the passing of time qi depression to blood stasis, venation block, blood is not supported skin and is formed; though pathological changes shows skin, with taste; internal organs such as Liver and kidney are closely related, whenever hinders outbreak repeatedly because feeling exopathogen or feelings will again; the course of disease is slow, and touching difficulty heals." element ask wind opinion a piece of writing " cloud " pathogenic wind hiding in the skin must not be let out outward, interior must not leading to, for a long time and blood stasis ".The endogenous cause of ill of vitiligo morbidity is mainly depression of liver-QI, prolonged illness consumption or qi depression to blood stasis, and the damage of essence insufficiency of blood, deficiency of the liver and kindey, inside and outside phase factor is eventually to qi-blood disharmony and send out and be primary disease.Leukodermic characteristics of incidence is this with the hepatic and renal YIN deficiency, and qi depression to blood stasis is mark, and wherein liver, kidney are topmost pathological changes internal organs, and excess syndrome is rare, is many with deficiency syndrome.So therapy for vitiligo should be controlled from the Liver and kidney opinion, based on depressed liver-energy dispersing and QI regulating, liver and kidney tonifying, holds concurrently with methods such as blood circulation promoting and blood stasis dispelling, invigorating spleen and dispelling wind-evils.Have at present both at home and abroad a variety ofly at the medicine of therapy of vitiligo, but curative effect is all imprecise, and have go back toxic side effect.
Summary of the invention
In order to solve the above-mentioned technical problem that exists in the background technology, the invention provides a kind of have than high curative rate, safety and have no side effect be used for the treatment of leukodermic pharmaceutical composition.
Technical solution of the present invention is: the invention provides a kind of leukodermic pharmaceutical composition that is used for the treatment of, its special character is: describedly be used for the treatment of leukodermic pharmaceutical composition and comprise that weight portion is the Fructus Psoraleae preparation of 12～30 parts the Radix Rehmanniae, 6～12 parts Radix Angelicae Sinensis, 12～25 parts Radix Paeoniae Rubra, 10～25 parts Caulis Spatholobi and 6～15 parts.
Above-mentionedly be used for the treatment of leukodermic pharmaceutical composition and comprise that also weight portion is the Rhizoma Chuanxiong of 6～12g part, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae and 12～25 parts Fructus Ligustri Lucidi.
Above-mentionedly be used for the treatment of leukodermic pharmaceutical composition and comprise that also weight portion is 10～15 parts Spica Prunellae and 3～6 parts Herba Menthae.
Above-mentionedly be used for the treatment of leukodermic pharmaceutical composition and comprise that also weight portion is 3～10 parts Radix Glycyrrhizae.
Above-mentionedly be used for the treatment of leukodermic pharmaceutical composition and comprise that weight portion is the Fructus Psoraleae preparation of 13～25 parts the Radix Rehmanniae, 8～11 parts Radix Angelicae Sinensis, 13～22 parts Radix Paeoniae Rubra, 13～24 parts Caulis Spatholobi and 8～14 parts.
Above-mentionedly be used for the treatment of leukodermic pharmaceutical composition and comprise that weight portion is the Fructus Psoraleae preparation of 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts.
Above-mentionedly be used for the treatment of leukodermic pharmaceutical composition and also comprise medically acceptable excipient.
The above-mentioned dosage form that is used for the treatment of leukodermic pharmaceutical composition is Chinese medicine granules, tablet, oral liquid or capsule.
Advantage of the present invention is:
The invention provides a kind of leukodermic pharmaceutical composition that is used for the treatment of, this pharmaceutical composition comprises plurality of Chinese such as the Radix Rehmanniae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Caulis Spatholobi, Radix Codonopsis, Fructus Psoraleae, Radix Scutellariae, Fructus Ligustri Lucidi, Spica Prunellae, Herba Menthae and Radix Glycyrrhizae.These Chinese medicines have depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, kidney and spleen invigorating, in addition, there are some researches show have dispersing the stagnated live-QI to relieve the stagnation of QI, the Chinese medicine of blood circulation promoting and blood stasis dispelling, expelling wind and removing dampness, nourishing the liver and kidney function, can also adjust body's immunological function, can make stable disease.In the prescription of Chinese medicine preparation of the present invention, Fructus Psoraleae, Fructus Ligustri Lucidi liver and kidney tonifying; Caulis Spatholobi enrich and benefit essence and blood, promoting blood circulation to remove obstruction in the collateral; Spica Prunellae, Herba Menthae liver clearing and depression relieving, the wind in the blood of dispelling; Radix Scutellariae heat clearing and damp drying, cooling blood for hemostasis; Herba Menthae, Rhizoma Chuanxiong are joined Radix Angelicae Sinensis, but the Radix Paeoniae Rubra circulation of qi promoting is soothing the liver, blood circulation promoting and blood stasis dispelling; But Radix Codonopsis is joined Radix Angelicae Sinensis, Rhizoma Chuanxiong tonifying QI to promote blood circulation, thereby makes " the capable then blood of gas is capable ".The Radix Rehmanniae, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Rhizoma Chuanxiong enrich blood nourishing blood and promoting blood circulation, disperse blood stasis and dredge collateral can promote that blood is capable, improve blood circulation, contain the meaning that " control wind and control blood earlier, the blood sector-style is from going out " arranged; Radix Glycyrrhizae reinforcing the heart spleen invigorating, the property of medicine that is in harmonious proportion; All medicines share the merit of playing nourishing the liver and kidney, nourishing blood to expel wind, blood circulation promoting and blood stasis dispelling altogether, thereby make the recovery of the unobstructed adjustment of blood operation pigment cell function.The present invention has depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, kidney and spleen invigorating, adjusting immunity, can promote functions such as melanocyte regeneration and melanic formation, surplus clinical tens thousand of routine patients ten, observe in year, be used for the treatment of vitiligo and have clinical efficacy preferably, and have no side effect.The present invention can prepare various dosage forms, such as tablet, oral liquid etc. be easy to carry, convenient drug administration, dosage is little, active constituent content height, strong drug action, mouthfeel is good, has reduced the inconvenience that long-term oral Chinese medicine decoction taste is bitter and boil medicine.
The specific embodiment
The present inventor develops the leukodermic pure Chinese medicinal preparation of the higher treatment of a kind of cure rate through long-term research practice, and drug safety and having no side effect.The prescription of this Chinese medicine preparation is: the Radix Rehmanniae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Caulis Spatholobi, Radix Codonopsis, Fructus Psoraleae, Radix Scutellariae, Fructus Ligustri Lucidi, Spica Prunellae, Herba Menthae, Radix Glycyrrhizae.Have depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, kidney and spleen invigorating, regulate functions such as immunity, can promote melanocyte regeneration and melanic formation.In addition, there are some researches show have dispersing the stagnated live-QI to relieve the stagnation of QI, the Chinese medicine of blood circulation promoting and blood stasis dispelling, expelling wind and removing dampness, nourishing the liver and kidney function, can also adjust body's immunological function, can make stable disease.In the prescription of Chinese medicine preparation of the present invention, Fructus Psoraleae, Fructus Ligustri Lucidi liver and kidney tonifying; Caulis Spatholobi enrich and benefit essence and blood, promoting blood circulation to remove obstruction in the collateral; Spica Prunellae, Herba Menthae liver clearing and depression relieving, the wind in the blood of dispelling; Radix Scutellariae heat clearing and damp drying, cooling blood for hemostasis; Herba Menthae, Rhizoma Chuanxiong are joined Radix Angelicae Sinensis, but the Radix Paeoniae Rubra circulation of qi promoting is soothing the liver, blood circulation promoting and blood stasis dispelling; But Radix Codonopsis is joined Radix Angelicae Sinensis, Rhizoma Chuanxiong tonifying QI to promote blood circulation, thereby makes " the capable then blood of gas is capable ".The Radix Rehmanniae, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Rhizoma Chuanxiong enrich blood nourishing blood and promoting blood circulation, disperse blood stasis and dredge collateral can promote that blood is capable, improve blood circulation, contain the meaning that " control wind and control blood earlier, the blood sector-style is from going out " arranged; Radix Glycyrrhizae reinforcing the heart spleen invigorating, the property of medicine that is in harmonious proportion; All medicines share the merit of playing nourishing the liver and kidney, nourishing blood to expel wind, blood circulation promoting and blood stasis dispelling altogether, thereby make the recovery of the unobstructed adjustment of blood operation pigment cell function.
Provided by the present inventionly be used for the treatment of leukodermic pharmaceutical composition and comprise that by weight portion be 12～30 parts the Radix Rehmanniae, 6～12 parts Radix Angelicae Sinensis, 12～25 parts Radix Paeoniae Rubra, 10～25 parts Caulis Spatholobi, 6～15 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 10～15 parts Spica Prunellae, 3～6 parts Herba Menthae and 3～10 parts the Radix Glycyrrhizae preparation of Fructus Psoraleae, 6～12g part; As preferably, can select weight portion is 13～25 parts the Radix Rehmanniae, 8～11 parts Radix Angelicae Sinensis, 13～22 parts Radix Paeoniae Rubra, 13～24 parts Caulis Spatholobi and 8～14 parts Fructus Psoraleae and the preparation of other component; Preferred, can select weight portion is 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae and the preparation of other component.
Except above-mentioned each necessary component, for the ease of preparation of pharmaceutical compositions provided by the present invention being become various dosage forms portable and easy to use, for example during medicament such as Chinese medicine granules, tablet, oral liquid or capsule, also need increasing some medically acceptable excipient in the above-mentioned component, soybean oil for example, starch, deionized water etc. can both be implemented in the present invention.
The present inventor obtains following optimal components ratio embodiment through long-term practice:
| Embodiment | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| The Radix Rehmanniae (g) | 12 | 14 | 18 | 22 | 25 | 28 | 30 | 12 | 14 | 15 | 17 | 19 | 21 | 22 | 23 |
| Radix Angelicae Sinensis (g) | 9 | 8 | 10 | 12 | 11 | 6 | 7 | 12 | 10 | 8 | 6 | 5 | 7 | 9 | 11 |
| Radix Paeoniae Rubra (g) | 25 | 22 | 20 | 18 | 16 | 14 | 12 | 11 | 13 | 15 | 17 | 19 | 21 | 23 | 25 |
| Caulis Spatholobi (g) | 10 | 13 | 16 | 19 | 21 | 23 | 24 | 25 | 23 | 21 | 24 | 19 | 15 | 14 | 17 |
| Fructus Psoraleae (g) | 15 | 14 | 13 | 10 | 9 | 7 | 6 | 14 | 10 | 9 | 6 | 7 | 12 | 14 | 11 |
| Rhizoma Chuanxiong (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 10 | 9 | 8 | 7 | 6 | 5 | 11 |
| Radix Codonopsis (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 15 | 28 | 10 | 22 | 30 | 11 | 15 |
| Radix Scutellariae (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 7 | 9 | 11 | 13 | 15 | 6 | 8 |
| Fructus Ligustri Lucidi (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 22 | 19 | 16 | 14 | 12 | 13 | 15 |
| Spica Prunellae (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Herba Menthae (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Radix Glycyrrhizae (g) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Embodiment | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| The Radix Rehmanniae (g) | 25 | 27 | 29 | 30 | 28 | 24 | 21 | 20 | 18 | 15 |
| Radix Angelicae Sinensis (g) | 12 | 10 | 8 | 9 | 6 | 7 | 8 | 10 | 12 | 13 |
| Radix Paeoniae Rubra (g) | 23 | 22 | 21 | 18 | 15 | 16 | 20 | 14 | 15 | 10 |
| Caulis Spatholobi (g) | 18 | 16 | 10 | 13 | 14 | 17 | 16 | 19 | 21 | 22 |
| Fructus Psoraleae (g) | 12 | 14 | 15 | 10 | 9 | 8 | 14 | 5 | 6 | 11 |
| Rhizoma Chuanxiong (g) | 7 | 9 | 11 | 12 | 14 | 8 | 8 | 7 | 10 | 9 |
| Radix Codonopsis (g) | 17 | 19 | 21 | 22 | 26 | 23 | 24 | 14 | 15 | 20 |
| Radix Scutellariae (g) | 9 | 10 | 12 | 14 | 8 | 7 | 9 | 5 | 11 | 12 |
| Fructus Ligustri Lucidi (g) | 17 | 19 | 21 | 22 | 13 | 14 | 25 | 18 | 21 | 16 |
| Spica Prunellae (g) | 13 | 15 | 12 | 10 | 12 | 14 | 15 | 16 | 13 | 15 |
| Herba Menthae (g) | 3 | 4 | 5 | 6 | 3 | 5 | 4 | 6 | 4 | 3 |
| Radix Glycyrrhizae (g) | 0 | 0 | 0 | 3 | 5 | 6 | 7 | 8 | 9 | 10 |
Several prescriptions in inventor's picked at random above-described embodiment, research has also been observed this Chinese medicine preparation pastille serum to melanocyte propagation and the synthetic influence of melanocyte by experiment.Adopt mtt assay to measure pastille serum to the influence (the results are shown in Table 1) of melanocyte propagation, the result shows through variance analysis, and group difference has significance (F=4.5456, P＜0.05).With the blank group relatively, this Chinese medicine preparation and positive controls can obviously promote melanocyte propagation (P is equal for q=49.49, q=55.45＜0.05), this Chinese medicine preparation group difference of comparing with positive controls does not have significance (q=2.86.P＞0.05).Adopt the NaOH method to observe the influence (the results are shown in Table 2) synthetic to melanocyte of this Chinese medicine preparation pastille serum simultaneously, experimental result shows this Chinese medicine preparation to melanocyte propagation and synthesizes all have obvious facilitation.
Table 1 is respectively organized MTT measurement result table 2 and is respectively organized NaOH measurement result (ng/10
6Cell)
Select for use provided by the present inventionly to be used for the treatment of leukodermic pharmaceutical composition when carrying out in vitro tests, choose different regions respectively, patients with vitiligo experimenter in various degree tests, and its result is as follows:
1, choose Radix Rehmanniae 14g, Radix Angelicae Sinensis 8g, Radix Paeoniae Rubra 22g, Caulis Spatholobi 13g and Fructus Psoraleae 14g (referring to embodiment 2) decoct with water 30 minutes, it is boiled be Chinese medicine decoction, slight patients with vitiligo 30 people are carried out human trial, male 21 people wherein, women 9 people, age distribution is in 20-39 year, sooner or later respectively take Chinese medicine decoction once every day, each 200～300ml, uses 3 courses for the treatment of continuously at 30 days each courses for the treatment of, each detailed inspection course for the treatment of has or not whole body and local untoward reaction, and itemized record to 3 end course for the treatment of, its result shows that 30 people all do not have part or systemic adverse reactions, and 19 people of obviously alleviating the vitiligo symptom and taking a favorable turn, can alleviate 3 people of vitiligo symptom, complete 8 invalid people, its total effective rate accounts for 73.3%.
2, choose Radix Rehmanniae 15g, Radix Angelicae Sinensis 8g, Radix Paeoniae Rubra 15g, Caulis Spatholobi 21g, Fructus Psoraleae 9g, Rhizoma Chuanxiong 9g, Radix Codonopsis 28g, Radix Scutellariae 9g and Fructus Ligustri Lucidi 19g (referring to embodiment 10) make the Chinese medicinal granule electuary according to a conventional method, 50 people carry out human trial to the moderate patients with vitiligo, male 26 people wherein, women 24 people, age distribution is in 35-45 year, morning, noon and afternoon every day are respectively taken the Chinese medicinal granule electuary once, about each 100ml, 30 days each courses for the treatment of, use 2 courses for the treatment of continuously, each detailed inspection course for the treatment of has or not whole body and local untoward reaction, and itemized record to 2 end course for the treatment of, its result shows, 50 people all do not have part or systemic adverse reactions, and 34 people of obviously alleviating the vitiligo symptom and taking a favorable turn, 5 people that can alleviate the vitiligo symptom, complete 11 invalid people, its total effective rate accounts for 78%.
3, choose Radix Rehmanniae 23g, Radix Angelicae Sinensis 11g, Radix Paeoniae Rubra 25g, Caulis Spatholobi 17g, Fructus Psoraleae 11g, Rhizoma Chuanxiong 11g, Radix Codonopsis 15g, Radix Scutellariae 8g, Fructus Ligustri Lucidi 15g, Spica Prunellae 11g and Herba Menthae 5g (referring to embodiment 15) make tablet after adding medically acceptable excipient (starch or soybean oil) according to a conventional method, 126 people carry out human trial to the moderate patients with vitiligo, male 69 people wherein, women 57 people, age distribution is in 25-49 year, sooner or later respectively take tablet once every day, each 3,30 days each courses for the treatment of, use 3 courses for the treatment of continuously, each detailed inspection course for the treatment of has or not whole body and local untoward reaction, and itemized record to 3 end course for the treatment of, its result shows, 126 people all do not have part or systemic adverse reactions, and 98 people of obviously alleviating the vitiligo symptom and taking a favorable turn, 12 people that can alleviate the vitiligo symptom, complete 16 invalid people, its total effective rate accounts for 87.3%.
4, choose Radix Rehmanniae 21g, Radix Angelicae Sinensis 8g, Radix Paeoniae Rubra 20g, Caulis Spatholobi 16g, Fructus Psoraleae 14g, Rhizoma Chuanxiong 8g, Radix Codonopsis 24g, Radix Scutellariae 9g, Fructus Ligustri Lucidi 25g, Spica Prunellae 15g, Herba Menthae 4g and Radix Glycyrrhizae 7g (referring to embodiment 22) make capsule after adding medically acceptable excipient (starch or soybean oil) according to a conventional method, 94 people carry out human trial to the moderate patients with vitiligo, male 26 people wherein, women 68 people, age distribution is in 20-55 year, morning, noon and afternoon every day are respectively taken capsule once, each 2,30 days each courses for the treatment of, use 3 courses for the treatment of continuously, each detailed inspection course for the treatment of has or not whole body and local untoward reaction, and itemized record to 3 end course for the treatment of, its result shows, 94 people all do not have part or systemic adverse reactions, and 85 people of obviously alleviating the vitiligo symptom and taking a favorable turn, 6 people that can alleviate the vitiligo symptom, complete 3 invalid people, its total effective rate accounts for 97%.
Claims (12)
1. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be the Fructus Ligustri Lucidi preparation of 12～30 parts the Radix Rehmanniae, 6～12 parts Radix Angelicae Sinensis, 12～25 parts Radix Paeoniae Rubra, 10～25 parts Caulis Spatholobi, 6～15 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae and 12～25 parts by weight portion.
2. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be the Herba Menthae preparation of 12～30 parts the Radix Rehmanniae, 6～12 parts Radix Angelicae Sinensis, 12～25 parts Radix Paeoniae Rubra, 10～25 parts Caulis Spatholobi, 6～15 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 10～15 parts Spica Prunellae and 3～6 parts by weight portion.
3. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be the Herba Menthae preparation of 12～30 parts the Radix Rehmanniae, 6～12 parts Radix Angelicae Sinensis, 12～25 parts Radix Paeoniae Rubra, 10～25 parts Caulis Spatholobi, 6～15 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 3～10 parts Radix Glycyrrhizae, 10～15 parts Spica Prunellae and 3～6 parts by weight portion.
4. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be the Fructus Ligustri Lucidi preparation of 13～25 parts the Radix Rehmanniae, 8～11 parts Radix Angelicae Sinensis, 13～22 parts Radix Paeoniae Rubra, 13～24 parts Caulis Spatholobi, 8～14 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae and 12～25 parts by weight portion.
5. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be the Herba Menthae preparation of 13～25 parts the Radix Rehmanniae, 8～11 parts Radix Angelicae Sinensis, 13～22 parts Radix Paeoniae Rubra, 13～24 parts Caulis Spatholobi, 8～14 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 10～15 parts Spica Prunellae and 3～6 parts by weight portion.
6. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be the Herba Menthae preparation of 13～25 parts the Radix Rehmanniae, 8～11 parts Radix Angelicae Sinensis, 13～22 parts Radix Paeoniae Rubra, 13～24 parts Caulis Spatholobi, 8～14 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 3～10 parts Radix Glycyrrhizae, 10～15 parts Spica Prunellae and 3～6 parts by weight portion.
7. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae and 12～25 parts Fructus Ligustri Lucidi preparation by weight portion.
8. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 10～15 parts Spica Prunellae and 3～6 parts Herba Menthae preparation by weight portion.
9. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 3～10 parts Radix Glycyrrhizae, 10～15 parts Spica Prunellae and 3～6 parts Herba Menthae preparation by weight portion.
10. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi and medically acceptable excipient preparation by weight portion.
11. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 10～15 parts Spica Prunellae, 3～6 parts Herba Menthae and medically acceptable excipient preparation by weight portion.
12. one kind is used for the treatment of leukodermic pharmaceutical composition, it is characterized in that: described to be used for the treatment of leukodermic pharmaceutical composition be to be 14～18 parts the Radix Rehmanniae, 9～10 parts Radix Angelicae Sinensis, 15～20 parts Radix Paeoniae Rubra, 16～22 parts Caulis Spatholobi and 10～13 parts Fructus Psoraleae, 6～12 parts Rhizoma Chuanxiong, 10～30 parts Radix Codonopsis, 5～15 parts Radix Scutellariae, 12～25 parts Fructus Ligustri Lucidi, 3～10 parts Radix Glycyrrhizae, 10～15 parts Spica Prunellae, 3～6 parts Herba Menthae and medically acceptable excipient preparation by weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210103185 CN102579678B (en) | 2012-04-11 | 2012-04-11 | Medicinal composition for treating vitligo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210103185 CN102579678B (en) | 2012-04-11 | 2012-04-11 | Medicinal composition for treating vitligo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102579678A CN102579678A (en) | 2012-07-18 |
| CN102579678B true CN102579678B (en) | 2013-10-02 |
Family
ID=46469280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210103185 Expired - Fee Related CN102579678B (en) | 2012-04-11 | 2012-04-11 | Medicinal composition for treating vitligo |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579678B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103461611A (en) * | 2013-10-09 | 2013-12-25 | 北京绿源求证科技发展有限责任公司 | Food health tea infusion dissolved medicine for improving vitiligo |
| CN109172784A (en) * | 2018-09-05 | 2019-01-11 | 黄珍英 | A kind of external-applied ointment for treating leucoderma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3183741B2 (en) * | 1993-02-18 | 2001-07-09 | ポーラ化成工業株式会社 | Complexion improver |
| CN1081463C (en) * | 1998-01-06 | 2002-03-27 | 宋守金 | External use medicine for vitiligo |
| JP2000070956A (en) * | 1998-08-28 | 2000-03-07 | Goshu Yakuhin Kk | Removing agent containing extract of galenical with hot water for free residual chlorine in water and bathing agent containing the same |
| CN1299737C (en) * | 2005-03-10 | 2007-02-14 | 靳瑞发 | Medicine for treating leukoderma and its preparing process |
| CN101049374B (en) * | 2007-04-25 | 2011-04-06 | 王家成 | Oral liquid for treating leucoderma, and preparation method |
| JP2007320970A (en) * | 2007-09-10 | 2007-12-13 | Naris Cosmetics Co Ltd | Cosmetic |
| CN101637512B (en) * | 2009-09-11 | 2011-09-28 | 刁保忠 | Traditional Chinese medicine preparation for treating vitiligo |
| CN102228544B (en) * | 2011-07-11 | 2012-07-04 | 山东新宝医药有限公司 | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
| CN102366468A (en) * | 2011-09-04 | 2012-03-07 | 成都绿迪科技有限公司 | Traditional Chinese medicine for treating vitiligo |
-
2012
- 2012-04-11 CN CN 201210103185 patent/CN102579678B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| JP特开2000-70956A 2000.03.07 |
| JP特开2007-320970A 2007.12.13 |
| JP特开平6-239758A 1994.08.30 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102579678A (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341004B (en) | Chinese medicine composition for treating delayed menstrual cycle | |
| CN101934052B (en) | Medicament for treating facial chloasma and preparation method thereof | |
| CN104127699A (en) | Vitality-tonifying health-preserving preparation and preparation method thereof | |
| CN100460008C (en) | Chinese medicine composition for treating cancer | |
| CN103272143A (en) | Traditional Chinese medicine composition for treating acne | |
| CN102698014A (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
| CN102716409B (en) | Traditional Chinese medicine composition for tonifying qi and nourishing blood | |
| CN102579678B (en) | Medicinal composition for treating vitligo | |
| CN104225450A (en) | Traditional Chinese medicine for treating depression | |
| CN103272159B (en) | Chinese herbal preparation used for treating consumptive disease and preparation method thereof | |
| CN105943705A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN105288232A (en) | Traditional Chinese medicine capsule for treating rheumatic bone disease and preparing method thereof | |
| CN102430097A (en) | Chinese medicine for treating vitiligo | |
| CN104840577A (en) | Traditional Chinese medicine for treating pantalgia after childbirth | |
| CN103550679A (en) | Traditional Chinese medicine formula for treatment of lithangiuria | |
| CN103071079B (en) | Traditional Chinese medicinal composition for treating prurigo nodularis | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN103751418A (en) | Traditional Chinese medicine composition for treating restless leg syndrome | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN103784893A (en) | Medicine for treating sequela of cerebra apoplexy | |
| CN103550469B (en) | A kind of Chinese medicine composition for the treatment of lumbago disease | |
| CN101912566B (en) | Traditional Chinese medicine for treating palpitation | |
| CN103230475B (en) | One treats psoriatic medicine | |
| CN102357218B (en) | Chinese medicinal composition for treating abnormal menstruation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: GAO TIANWEN Effective date: 20140808 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140808 Address after: 710032 Changle West Road, Shaanxi, China, No. 127, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032 Department of Dermatology, Xijing Hospital, 15 West Changle Road, Xi'an, Shaanxi Patentee before: Gao Tianwen |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131002 Termination date: 20150411 |
|
| EXPY | Termination of patent right or utility model |